RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:rbc update wow scripts... all up againThis article is filled with assumptions and speculation. It appears to be written by you Lattice or someone on your team. A desperate move to try and move this stock even lower while a deal is being negotiated to help the company's balance sheet and shareholders. Move one. You and your cohort gang of crooks have caused enough damage to countless shareholders.
Craigbad wrote: Excellent article, thanks for the link. This goes a long way to explaining why they are so desperate that they are willing to go to pirate equity for a cash injection. I knew the headwinds were strong, but it looks like survival is in jeopardy sooner rather than later.
LaticelnExile wrote: Lumberfeverlong, Here is a fantastic piece of research on AMCo drug pricing, although I know you will continue to say its "short and distort" and continue to pump this trainwreck while shareholders test new 52 week lows WOW.
Seven pennies off for a new 52 week low for CXRX!
https://seekingalpha.com/article/4009942-concordia-international-depth-look-amcos-drug-price-gouging
Lumberfeverlong wrote: There definitely were those two examples you have given in the past, but that is a far cry from 2,500% and 2,700%.
LaticelnExile wrote: Yes! Of course! My data is the same as Billy Kenber' s data that is publically available - if youhave the time and inclination to go through the nhs tariff books. I have noted AMCo price increases ranging from 500% to 1400% on select drugs in my previous posts. Good luck to all.
Lumberfeverlong wrote: There are a bunch of "in the event", "could" and "believe" qualifiers in the passage. Moreover, the inestigation with Flynn and Pfizer appears to relate to increasing prices by 25 to 27 times historical levels. I am not aware of any drug in the Concordia portfolio that comes close to that. Do you Lattice?
LaticelnExile wrote:
patenright11 wrote: FLYN AND PFIZER, THAT IS NOT CONCORDIA LETTUCE PHUC HEAD.
HERE YOU GO .... This explains the relevancy, from the RBC Report to Investors. Decision has not been made yet by the CMA. Doesn't look good tho', IMO
Key points:
Outcome of Flynn Pharma/Pfizer Competition and Marketing Authority (CMA) investigation potentially relevant to AMCo pricing behaviour.
Flynn and Pfizer are alleged to have sold an epilepsy drug, phenytoin sodium, with little competition, to the NHS for 25-27 times higher than historical prices. In the event that the CMA determines Pfizer/ Flynn's behaviour impaired genuine competition and drug pricing was excessive and unfair and fines the companies etc..., we believe attention could turn to other companies which have significantly increased the prices of certain drugs, including Concordia, and this could place an additional overhang on the shares if the outcome were negative.